Interestingly, some of these upregulated markers are known to be associated with antitumor immunity, such as HMGN1 (Wei et al., 2014); the transcription factor CREB1 that plays a key role in NF‐kB inhibition, thereby limiting proinflammatory responses and enhancing host immune responses (Wen et al., 2010); IRF1 that contributes to tumor immune surveillance (Dou et al., 2014). The gene discussed is NFKB1; the disease is neoplasm.